Bevacizumab beyond disease progression for advanced non–small cell lung cancer: Does persistence have its rewards?

Persistence pays off when it comes to the vascular endothelial growth factor inhibitor bevacizumab in non–small cell lung cancer patients who have progressed on first-line chemotherapy. Continued vascular endothelial growth factor blockade after progression on first-line therapy may provide at least a modest benefit when it is continued with second-line chemotherapy. See also pages 000–000

from Cancer via ola Kala on Inoreader http://ift.tt/1STzaXs
via IFTTT